注射用英夫利昔单抗的临床疗效及安全性

Clinical Efficacy and Safety of Infliximab for Injection

目的:探讨注射用英夫利昔单抗的临床疗效和安全性,为临床合理用药提供参考。方法:回顾性分析2010年6月-2011年11月某院66例患者静脉滴注英夫利昔单抗治疗慢性免疫性疾病的情况,查阅患者治疗前、后症状、体征以及病原学检查情况。结果:66例患者共注射英夫利昔单抗283次。第1次注射后C反应蛋白(CRP)即达到正常值或者降低明显的患者占66.7%(20/30),所有患者CRP在住院期间或门诊随访时的复查结果中恢复至正常值;第1次注射后血沉即达到正常或降低明显的患者占51.4%(18/35),好转率为68.6%(24/35);注射后类风湿因子明显减少的患者占80.0%(24/30)。有48例出现轻、中度氨基转移酶升高,未出现过敏等。结论:英夫利昔单抗疗效明确,用药过程中可能会引起氨基转移酶升高,在临床用药时需要注意监测。

OBJECTIVE ： To investigate the clinical efficacy and safety of Infliximab for injection, and to provide reference for rational drug use in the clinic. METHODS： 66 patients with chronic autoimmune diseases, who used Infliximab for injection intra- venously in a hospital during Jun. 2010--Nov. 2011 were analyzed retrospectively. The symptoms and signs as well as the pathogen- ic examination were reviewed before and after treatment. RESULTS： Infliximab for injection was used for 283 times in 66 cases. CRP of 20 cases returned to normal immediately or decreased significantly after first injection （66.7%, 20/30）; CRP of all patients returned to normal during hospitalization stay and outpatient following-up. Erythrocyte sedimentation of 18 cases returned to normal or decreased significantly after first injection （51.4%, 18/35） with recovery rate of 68.6%. Rheumatoid factor of 24 cases recovered significantly after injection （80.0%, 24/30）. Mild to moderate elevated transaminase was found in 48 cases and no allergy was ap- peared. CONCLUSIONS： Infliximab shows accurate curative effect and induces the elevation of transaminase during treatment. The use of it should be monitored in the clinic.